Long-acting injectable HIV PrEP patient experience
Part of Infections clinical trials.
This study is for people who are already taking or about to start long-acting injectable HIV PrEP (shots instead of daily pills). The goal is to learn about your experiences and preferences with this type of PrEP. It takes place in Louisville, Kentucky.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your doctor has said you are eligible for HIV PrEP (medication to prevent HIV).
- You are currently taking or will start a long-acting injectable HIV PrEP (like Cabotegravir or Lenacapavir) within 30 days.
- You receive your PrEP care in Louisville, Kentucky.
- You do not have HIV.
- You are not taking oral PrEP with no plans to switch to injectable.
- You have no allergies to the HIV PrEP shots.
- You are not pregnant and do not plan to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study offers a long-acting injectable form of PrEP (lenacapavir) to prevent HIV in Latine transgender women and gay men in the South. It aims to make HIV prevention easier by providing a shot instead of a daily pill.
This study follows people taking a new long-acting HIV prevention injection called LA CAB (cabotegravir). Researchers want to understand how well it works, how people use it, and what side effects occur in real-world NHS clinics.
This trial tests a nurse-run program that makes it easier to get long-acting injectable PrEP (cabotegravir) for HIV prevention. It aims to see if nurses can start and provide this shot quickly at your regular clinic visits.
This study helps healthcare providers and clinics deliver long-acting injectable PrEP (a preventive HIV medication given as an injection) more effectively. Researchers will study how clinics can better implement and offer this option to patients who need it.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study follows people who are stopping long-acting injectable PrEP (cabotegravir or lenacapavir). It checks how long the drug stays in your body and helps make sure you stay protected during that time. You'll do monthly video visits, mail in blood samples, and fill out short surveys.
Hear when a new HIV Pre-exposure Prophylaxis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.